https://www.onhealthcare.tech/p/eli-lillys-triple-agonist-retatrutide-fc8Thoughts on Healthcare Markets & Technologyen2026-05-23T21:45:12+00:00Eli Lilly’s triple agonist retatrutide hits 28.3% mean weight loss in TRIUMPH-1 phase 3, blowing past tirzepatide benchmarks & rewriting obesity math for payers, PBMs & the Lilly Novo Duopolyhttps://www.onhealthcare.tech/p/eli-lillys-triple-agonist-retatrutideThoughts on Healthcare Markets & Technologyen2026-05-23T21:27:39+00:00Eli Lilly’s triple agonist retatrutide hits 28.3% mean weight loss in TRIUMPH-1 phase 3, blowing past tirzepatide benchmarks & rewriting obesity math for payers, PBMs & the Lilly Novo Duopolyhttps://www.onhealthcare.tech/p/forus-just-raised-160m-at-a-1b-valuationThoughts on Healthcare Markets & Technologyen2026-05-22T15:19:03+00:00Forus Just Raised $160M at a $1B Valuation to Become the Operational Routing Layer for Specialty Rx & the Real Story Is Why Investors Now Believe Healthcare Orchestration Beats SaaShttps://www.onhealthcare.tech/p/part-ii-forus-just-raised-160m-atThoughts on Healthcare Markets & Technologyen2026-05-22T14:22:14+00:00Part II: Forus Just Raised $160M at a $1B Valuation to Become the Operational Routing Layer for Specialty Rx & the Real Story Is Why Investors Now Believe Healthcare Orchestration Beats SaaShttps://www.onhealthcare.tech/p/part-i-forus-just-raised-160m-atThoughts on Healthcare Markets & Technologyen2026-05-22T14:10:47+00:00Part I: Forus Just Raised $160M at a $1B Valuation to Become the Operational Routing Layer for Specialty Rx & the Real Story Is Why Investors Now Believe Healthcare Orchestration Beats SaaS